Functional dyspepsia: how could a biliary dyspepsia sub-group be recognized? A methodological approach.
Functional dyspepsia (FD) includes a heterogeneous group of patients suffering from a variety of different conditions. The Dyspepsia Project has been implemented in 14 GI Units since 1984, in order to epidemiologically test the discriminating power of the Working Teams definitions and of standardized questionnaires. Five per cent of admitted subjects were subclassified as sphincter of Oddi dysfunction or biliary dyspepsia (BD), defined as biliary pain associated or not to bilirubin or alkaline phosphatase elevation, in the abscence of ultrasonographic evidence of gallstone disease or bile duct dilatation. The more useful symptoms in favour of the diagnosis of biliary dyspepsia were found to be pain in the right hypochondrium, radiating to the shoulder, or to the back, initiated by food, and eventually associated with constipation, or epigastric postprandial discomfort. Interestingly, symptoms suggesting biliary dyspepsia are partially shared by dysmotility-like dyspepsia. The placebo response in functional dyspepsia is variable, between 6 and 80% of patients, reflecting variations in the kind and severity of the diseases in different studies. That represents a considerable difficulty in evaluating drug efficacy, even in the case of biliary dyspepsia. A therapeutic double-blind trial in functional dyspepsia using tauro-ursodeoxycholic acid is discussed.
Koch
M
M
Dipartimento Malattie Digestive e Nutrizionali, Azienda Ospedaliera, Ospedale S. Filippo Neri, Roma, Italy.
Capurso
G
G
D000328:Adult; D001660:Biliary Tract Diseases / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D004415:Dyspepsia / Q000209:etiology* / Q000628:therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D013655:Taurochenodeoxycholic Acid / Q000627:therapeutic use
D013655:Taurochenodeoxycholic Acid; C031655:ursodoxicoltaurine